Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for AJANTPHARM.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for AJANTPHARM.BO and 80,000+ other tickers.
See exactly how AJANTPHARM.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AJANTPHARM.BO and 80,000+ other tickers.
Operating as a specialized pharmaceutical company, Ajanta Pharma Limited, together with its subsidiaries, is involved in the entire lifecycle of finished drug formulations, from their development and manufacturing to market distribution. Its comprehensive portfolio caters to diverse therapeutic segments, including treatments for malaria, cardiovascular conditions, eye care, skin disorders, pain, digestive health, allergies, respiratory illnesses, and diabetes. The company produces a wide array of pharmaceutical forms, such as tablets, capsules, powders, liquids, jellies, ointments, sterile…
No recent news available.